Abstract
Background
Antibodies targeting epidermal growth factor receptor (EGFR), such as cetuximab, may potentially improve outcome in non-small cell lung cancer (NSCLC) patients with high EGFR expression. The EGFR expression may be heterogeneously distributed within tumors, and small biopsies may thus not accurately reveal the EGFR expression. In addition, EGFR expression may also change during chemotherapy. The current study investigates the magnitude of these two issues.
Materials and methods
EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples.
Results
Discordance between tumors dichotomized according to EGFR expression (high: H-score ≥200; low: H-score <200) in diagnostic biopsies and immediate resection specimens was 25 % in the OP group and 33 % in the NAC group (p = 0.628). Five (9 %) of primary tumors in the OP group and 4 (13 %) in the NAC group had increased EGFR expression in the resection specimens as compared to the diagnostic biopsies (p = 0.583). A decrease in EGFR expression was observed in 6 (11 %) in the OP group and 7 (23 %) in the NAC group (p = 0.148).
Conclusion
EGFR expression in 25 % of diagnostic biopsies may potentially not be accurate compared to the prevailing pattern in the whole tumor based on the larger resection specimens. This may potentially be an obstacle for proper use of antibodies targeting the EGFR in NSCLC. EGFR expression does, however, not change significantly during paclitaxel and carboplatin and rebiopsies in order to decide on anti-EGFR antibody therapy following chemotherapy do not seem warranted.
Similar content being viewed by others
References
Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TPJ, Leahy DJ et al (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12(3):541–552
Pérez-Soler R (2004) HER1/EGFR targeting: refining the strategy. Oncologist 9(1):58–67
Yarden Y (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4):S3–S8
Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145
Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–15
Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20):2040–2048
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634
Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K et al (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13(1):33–42
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957
Jakobsen J, Santoni-Rugiu E, Ravn J, Sorensen J (2013) Intratumor variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer. Eur J Cancer. doi:10.1016/j.ejca.2013.04.003
Meert AP, Martin B, Verdebout JM, Paesmans M, Berghmans T, Ninane V et al (2004) Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer 44(3):295–301
Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E et al (2007) Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 18(6):1043–1050
Grob TJ, Hoenig T, Clauditz TS, Atanackovic D, Koenig AM, Vashist YK et al (2013) Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. Lung Cancer 79(3):221–227
Pápay J, Sápi Z, Egri G, Gyulai M, Szende B, Losonczy G et al (2009) Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1. Pathol Oncol Res 15(3):445–450
Junker K, Stachetzki U, Rademacher D, Linder A, Macha HN, Heinecke A et al (2005) HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer 48(1):59–67
Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S et al (2012) Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 30(25):3077–3083
Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K (2008) Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99(5):929–935
Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V et al (2008) Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 99(6):923–929
Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L et al (2009) Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol 4(10):1212–1220
Chang YL, Wu CT, Shih JY, Lee YC (2011) Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. Ann Surg Oncol 18(2):543–550
Italiano A, Vandenbos FB, Otto J, Mouroux J, Fontaine D, Marcy PY et al (2006) Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol 17(6):981–985
Rao C, Hu Q, Ma J, Li J, Zhang C, Shen L et al (2010) Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy. J Exp Clin Cancer Res 29:7
Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G et al (2008) A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 14(12):3867–3874
De Pas T, Pelosi G, de Braud F, Veronesi G, Curigliano G, Leon ME et al (2004) Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol 22(24):4966–4970
Acknowledgments
We thank Camilla Cordua Mortensen, Heidi Ugleholdt, and Lone Svendstrup for expert technical assistance. This study was supported by the Danish Cancer Research Foundation, Arvid Nillsons Foundation, Torben and Alice Frimodts Foundation, Aase and Ejnar Danielsens Foundation, Eva and Henry Fraenkels Foundation, The Danish Research Foundation, Snedkermester Sophus Jacobsen and Hustru Astrid Jacobsens Foundation, The Foundation for the Promotion of Medical Cancer Treatment, and The Research Foundation of the Department of Oncology, Rigshospitalet.
Conflict of interest
The authors Jan Nyrop Jakobsen and Eric Santoni-Rugiu did not declare any conflicts of interest, and Jens Benn Sørensen received speaker’s fee from Roche.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jakobsen, J.N., Santoni-Rugiu, E. & Sørensen, J.B. Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer. Cancer Chemother Pharmacol 73, 131–137 (2014). https://doi.org/10.1007/s00280-013-2329-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-013-2329-0